or Try an Advanced Search...

    Technical Analysis for INVA - Innoviva, Inc.

    Grade Last Price % Change Price Change
    B 15.26 1.80% 0.27
    INVA closed up 1.8 percent on Friday, April 26, 2024, on 55 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    Earnings due: May 7
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical INVA trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Centerline Cross Bullish 0.00%
    Fell Below 50 DMA Bearish 1.80%
    NR7 Range Contraction 1.80%
    Gapped Down Weakness 1.80%
    Inside Day Range Contraction 0.66%
    Crossed Above 50 DMA Bullish 0.59%
    Expansion Pivot Buy Setup Bullish Swing Setup 0.59%
    Pocket Pivot Bullish Swing Setup 0.59%
    Upper Bollinger Band Touch Strength 0.59%
    Older End-of-Day Signals for INVA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Upper Bollinger Band about 14 hours ago
    60 Minute Opening Range Breakout about 16 hours ago
    Possible NR7 about 16 hours ago
    Up 1% about 17 hours ago
    Rose Above Previous Day's High about 20 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    INVA Chart by TradingView
    Basic chart:

    Profile

    Innoviva, Inc. Description

    Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Drugs Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Glucocorticoids Antero Corticosteroid Organofluorides Respiratory Products Combination Drugs Fluticasone

    Is INVA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
    Apr 22 Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
    Mar 4 Armata enters $35M credit agreement with Innoviva
    Mar 4 Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
    Feb 29 Innoviva GAAP EPS of $0.76, revenue of $85.84M beats by $10.32M
    Feb 29 Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
    Feb 29 Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
    Feb 14 Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition
    Jan 10 If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
    Dec 30 Innoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three years
    See more INVA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.865
    52 Week Low 11.38
    Average Volume 753,878
    200-Day Moving Average 14.33
    50-Day Moving Average 15.02
    20-Day Moving Average 14.80
    10-Day Moving Average 14.85
    Average True Range 0.31
    RSI (14) 59.84
    ADX 15.45
    +DI 26.11
    -DI 16.63
    Chandelier Exit (Long, 3 ATRs) 14.46
    Chandelier Exit (Short, 3 ATRs) 15.25
    Upper Bollinger Bands 15.30
    Lower Bollinger Band 14.31
    Percent B (%b) 0.96
    BandWidth 6.71
    MACD Line 0.02
    MACD Signal Line -0.06
    MACD Histogram 0.0847
    Fundamentals Value
    Market Cap 977.96 Million
    Num Shares 64.1 Million
    EPS 0.75
    Price-to-Earnings (P/E) Ratio 20.35
    Price-to-Sales 3.46
    Price-to-Book 1.60
    PEG Ratio 0.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.72
    Resistance 3 (R3) 15.68 15.48 15.64
    Resistance 2 (R2) 15.48 15.36 15.50 15.62
    Resistance 1 (R1) 15.37 15.29 15.43 15.41 15.59
    Pivot Point 15.18 15.18 15.20 15.20 15.18
    Support 1 (S1) 15.07 15.06 15.12 15.11 14.93
    Support 2 (S2) 14.87 14.99 14.89 14.90
    Support 3 (S3) 14.76 14.87 14.88
    Support 4 (S4) 14.80